{"name":"Arshad Khanani","slug":"arshad-khanani","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNSVp6aFl0cDBTRG1PSC1wQWxvRUJiSmVncHRLdnd2X0hqWDc4dFNTeERPX3Bva2VRVmNjTldzajhrVlBUeTZBYjNUb3VJWmc5NzE2NHRqN3Y2TnBkcEtYQnhoYUw4eC1meFJ4VWxrc250cld4RElRQmZaM3d6cENLQ2Rqblc2b3gtMjg3R1lFS3hfdG1PS0JWV1JHVlVQMzNpbnBtaFJ2Q2hKNE00WFRpTFEweUhXSVhyVkE?oc=5","date":"2026-02-20","type":"regulatory","source":"BioPharma APAC","summary":"Kato Wins FDA Approval for Human Studies of Drug for Retinal Disorders - BioPharma APAC","headline":"Kato Wins FDA Approval for Human Studies of Drug for Retinal Disorders","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQazRiU2QySU9EWFpxczI2alZmOVliSEdRUi14SFJIMzlwcnljbHNzU0NQZGhkOWJxRkxlU2xjYzhYZ3BZLV9yTjFrTENadWFjRVlJM1lPckpISUw2NWozZDFzeVZsRmVJdHNUWWExYlVpTzdFUzQ2NzUzTF9LazV3REtQNkdhNnRicnplNTYxaThLZE50TmVRY3B4Z1NpZWVtOWl5NmFUa2RKeUJicXloY2RRVVZGS2ttc3o1RGtB?oc=5","date":"2026-02-17","type":"regulatory","source":"Fierce Pharma","summary":"Ocular Therapeutix eyes FDA filing with ph. 3 wet AMD win over Eylea, but investors balk - Fierce Pharma","headline":"Ocular Therapeutix eyes FDA filing with ph. 3 wet AMD win over Eylea, but investors balk","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNSHREZDlGc3I2dkRnaXVGdkdhdnFfX1ZsY1dYMmtENkI3VVp1dmxFbHd0Y0xaMFFxZTBlSXF4WTNJMFlIaUJxcTJLSWgxQTZpeTRvYlp1NHRUYXE2MjgtVHBmamM5LXJlTWF5RGQyb2RrSnZTNjB0WDg1bElQV3FYVDNhUUlMRGtBR0NqYkJxU0JjNXhlS1VLYXZMNVhpLUdwS1JGWU50SjY1bGlER29GM0lZSQ?oc=5","date":"2026-02-13","type":"deal","source":"Fierce Pharma","summary":"Astellas casts retina specialists as 'Partners in Protection' in Izervay HCP campaign - Fierce Pharma","headline":"Astellas casts retina specialists as 'Partners in Protection' in Izervay HCP campaign","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQYWk1cm8zTHBMcHFYUXlWcTBEdlhrcVBwSE1nR1VxaW9fd2plV04zNlU1LXJXbDlDSDVuaHRGSzBueGVwbXhSLWlYamZXWkN3QUJmZFctWVQxSkFSRGRWOW0yYzRJb3pQLW5oaEtNTFJPVWh3VW8weUhBc0x5Q3ctenhwMm1obDJraEdpc29QQnhNRkwyd1Z1bjNzdVNmQk5oTHRDdm5JT0QtMFk?oc=5","date":"2024-11-12","type":"pipeline","source":"Medscape","summary":"Dry AMD Highlights From ASRS 2024 - Medscape","headline":"Dry AMD Highlights From ASRS 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPNDJPczl6czlmR1E5c2JRY1JrMVplQmo4QWl6OXF5WThKLVFvdV9ndjBPbzE3OWdIVHF3OV9qTmJBaWNENWJIVXJJOEdIZ3NxdnB4WHZRSG82S2NtaktBeHhSd3VPdU1hbUZwU0F0SHV4YVl3VlBLYkZHUlpHMGp2amR5cmRIS0E3dG0xQg?oc=5","date":"2024-04-02","type":"trial","source":"modernretina.com","summary":"Clinical trials: Companies tackle AMD in early 2024 - modernretina.com","headline":"Clinical trials: Companies tackle AMD in early 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPenR1bE9LczZlSVVRX1YyQkU3TV9SUjUyX0kxSXgtek1FYWdvWHZKMmtNLTBTaEpWSmVwN3VwYzFuWVpiM1gyVElxTFBiY2FUeTEyN3FaWENEdlgwM0tkWmFLbWZFcW02WFJTaHh0Qy1ZLVdFZ3hQQXY1d2ZOTnBwUXl2eFlkNzRDMzE4M2RIMV9PNVhTd3dfLW1pSVpEcW1VN3gtOEpBWVFwVHJvdzRlQlVZTDlGNGNsNXhn?oc=5","date":"2024-02-20","type":"pipeline","source":"Eyes On Eyecare","summary":"Opthea names Arshad M. Khanani, MD, MA, FASRS, as chief medical advisor - Eyes On Eyecare","headline":"Opthea names Arshad M. Khanani, MD, MA, FASRS, as chief medical advisor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNREZSV2tZamJBdTNOMllRUWRDTnpSQkNxU2VNT21RNVpoakNBRnVRcGNqSGFGcmx0VkR3MkVLd2xTZ0dZTFFfYk5nMGd6MHN1VEdGY091R1paUGxuTzhTWHNuLU0zTTNkZURsNlg2Qk53bjJMdVF0WEdyOGZ2UlhEeXhZd1h0RDY3Njdhclo5SkNaRFZScG42SWFlUTdseFFxSWk2THFR?oc=5","date":"2023-08-07","type":"regulatory","source":"Healio","summary":"Izervay receives FDA approval for geographic atrophy - Healio","headline":"Izervay receives FDA approval for geographic atrophy","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQV0dQOWlIcXVYUzkwWFZ3OC1XT1U3dU51c0FJM0VkMGxlVEUyQ3FJU3A5QmdyNU5ZZVpLOVpmZndFR3FTYmt0S3pmZ09PYWdycWdqeDVRSmNzTVNoeVpRUFdleXVBcUlSblo3UjRPV0pjUnhYNXpyblhlMUpWYVRyVi1YTVJjNEhYd0Nsd1E4VUJkM21qSWVxRUlDWHcwdzkzSHBTNnJKVHFtcmhVaGk1aHNuTTh3TGE1dmtpcGw5elh2akR6MXc?oc=5","date":"2023-08-07","type":"regulatory","source":"Fierce Pharma","summary":"Astellas wins FDA approval of eye disease drug Izervay and may have edge in market battle with Apellis - Fierce Pharma","headline":"Astellas wins FDA approval of eye disease drug Izervay and may have edge in market battle with Apellis","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxQSU1GeThyaDBtMXF1NVVJZjhrd3l5ajFtU0J6d041ekVhZ01ISFVDeHFvcWtOUWpjazl4NmF0RjlCd09TaE1YWTVOZ2ZEbktLY3FYNHhwSHZrZ3I5NHB3T29WWHJjVmgzZ04yNVBiMlpudTRFTEdxQjhEZWdyLVgxTDVhdnpEa1AxODhZU2UtaEgtcnZ2SlhzX0ctS3BoWWs4NFNDNXJhMTUwSTVTcU5vOHJNbjlMNF9FX284aUpiVDR6TUotVzRuR2d1aDhxc2I4NUE?oc=5","date":"2023-08-06","type":"regulatory","source":"Ophthalmology Times Europe","summary":"FDA issues approval for Iveric Bio avacincaptad pegol intravitreal solution for treatment of geographic atrophy - Ophthalmology Times Europe","headline":"FDA issues approval for Iveric Bio avacincaptad pegol intravitreal solution for treatment of geographic atrophy","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNQ1Z5ZEpxNkhMcWtEeUswRWlTWUpETGVXZW1vLXhiZDdhOTJjM01ZbFJCQnFqc3BBUEJsVWt2blgtamx0RDI5cW05bElYTUlYVTJQN3BxbjdOT3R4WVlkTzdLcV9nOS1LSDFMOFlpVTZ5Y0dER3BNMmJUQW9kQldFeXhVdTZjSWdhOGlNcUVvUkhIeERuNkRvUVRDSlc0TlhtTmM4cW04c085WTNoY0ZnS1BUWWg?oc=5","date":"2022-07-14","type":"pipeline","source":"Fierce Pharma","summary":"In pursuit of Bayer and Regeneron's Eylea, Roche shows Vabysmo's superior staying power - Fierce Pharma","headline":"In pursuit of Bayer and Regeneron's Eylea, Roche shows Vabysmo's superior staying power","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}